thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
November 2: Law on the labor of children, underage girls, and women in industrial establishments. November 30: Law on the practice of medicine: midwives are prohibited from prescribing medication, they may administer smallpox vaccines, and during childbirth, they are forbidden from using instruments and must call a physician or health officer in case of complications. 1893
=== Healthcare === On 11 January, Lula signed into law the "National Policy for the Prevention of Self-Mutilation and Suicide", created by the Health Ministry with the objective of giving mental health support for public security agents. On 20 January, Lula signed a bill, classifying community and disease control agents as health professionals. Also on 20 January, under pressure from religious entities, Lula created the "Department of Support for Therapeutic Communities", aimed at treating drug addicts; after the measure was criticized by human rights organizations, the Ministry of Social Development and Fight against Hunger announced that it would review the decision. The Brazilian Association of Mental Health had also spoken out against the measure in a repudiation note. On 8 March, International Women's Day, Lula announced the creation of the "Programme for the Protection and Promotion of Menstrual Dignity", which provides distribution of menstrual pads by the Sistema Único de Saúde (SUS) to people in vulnerable situations, below the Poverty threshold. The document regulates the Law nº 14.214/2021, which had been vetoed by Jair Bolsonaro in 2021. 8 million people will benefit from the initiative, according to specialists, with an investment of 418 million reals per year, according to the Ministry of Health.
The Cave of the High Place in the Small Valley (Cave 181), also called the "Highest Cave", is described extensively by Albert Grünwedel, as a particularly interesting cave of the small ravine. He explains that the cave is located high up on the right side of the ravine, which accounts for the fact that its murals have been preserved from the usual iconoclastic vandalism: the faces in particular are well preserved. Also, the murals did not use gold foils for decoration, which reduced the incentive for theft. In his plates, Grünwedel illustrates the murals of the cave, where he names the cave by its official name: Hochliegende Höhle der 2. Schlucht ("Cave of the High Place in the 2nd Valley"), which is the German name for cave 181. Grünwedel explains that the structure of the cave is extremely rare, as it is not a barrel-vaulted cave: instead, the ceiling has the shape of a tent. The flatness of the sides of the tent-like ceiling is the reason why Grünwedel was able to remove easily most of the ceiling paintings in large panels, something which is impossible with the strongly curved surface of a barrel-vaulted ceiling. The tent-like ceiling is bordered by a row of seven bejewelled princes on each side. The side wall depict rather tumultuous scenes of the sermon of the Buddha, no fewer than eight of them, with a multitude of attendants in various attitudes and clothing. The entrance wall had paintings of Tocharian donors and monks on both side. Above the entrance was the usual painting of Maitreya with surrounding Devaputras.
If administered in the form of a radiocolloid it tends to concentrate in the liver. Experiments in rats and monkeys suggest that astatine-211 causes much greater damage to the thyroid gland than does iodine-131, with repetitive injection of the nuclide resulting in necrosis and cell dysplasia within the gland. Early research suggested that injection of astatine into female rodents caused morphological changes in breast tissue; this conclusion remained controversial for many years. General agreement was later reached that this was likely caused by the effect of breast tissue irradiation combined with hormonal changes due to irradiation of the ovaries. Trace amounts of astatine can be handled safely in fume hoods if they are well-aerated; biological uptake of the element must be avoided.
GAHT may limit fertility potential. Should a transgender individual choose to undergo gender-affirming surgery, their fertility potential is lost completely. Before starting any treatment, individuals may consider fertility issues and fertility preservation. Options include semen cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation. A study presented at ENDO 2019 (the Endocrine Society's conference) shows that even after one year of treatment with testosterone, a transgender man can preserve his fertility potential. A 2015 study demonstrated normal spermatogenesis in some transgender women who were long-term estrogen therapy patients. In other cases, there is some research showing effective restoration of fertility by alternative means than HRT cessation alone. Dr. Will Powers has demonstrated the effectiveness of clomifene in restoring spermatogenesis in trans women. His study also includes an in-depth description of other methods for fertility restoration.
Sources: en.wikipedia.org
In early 1954, he wrote the article "Cobalt 60 – Danger or Blessing for Mankind?", about the misuse of atomic energy, which was widely reprinted and transmitted in the radio in Germany, Norway, Austria, and Denmark, and in an English version worldwide via the BBC. The international reaction was encouraging. The following year he initiated and organised the Mainau Declaration of 1955, in which he and other international Nobel Prize-winners called attention to the dangers of atomic weapons and urgently warned the nations of the world against the use of "force as a final resort", and which was issued a week after the similar Russell-Einstein Manifesto. In 1956, Hahn repeated his appeal with the signature of 52 of his Nobel colleagues from all parts of the world. Hahn was also instrumental in and one of the authors of the Göttingen Manifesto of 13 April 1957, in which, together with 17 leading German atomic scientists, he protested against a proposed nuclear arming of the West German armed forces (Bundeswehr). This resulted in Hahn receiving an invitation to meet the Chancellor of Germany, Konrad Adenauer and other senior officials, including the Defense Minister, Franz Josef Strauss, and Generals Hans Speidel and Adolf Heusinger (who had both been generals in the Nazi era). The two generals argued that the Bundeswehr needed nuclear weapons, and Adenauer accepted their advice. A communiqué was drafted that said that the Federal Republic did not manufacture nuclear weapons, and would not ask its scientists to do so.
=== China === There are no regulations on beak trimming in the People's Republic of China. Some companies have decided to voluntarily phase out debeaking, such as Ningxia Xiaoming Farming and Animal Husbandry Co. Ltd.
The Gallery of Botany is on the Allée the Buffon facing the centre of the garden, between the Gallery of Mineralogy and the Gallery of Palaeontology. At the corner is one of the two oldest trees in Paris, a Robinia pseudoacacia or black locust, planted in 1635 by Vespasien Robin, the royal gardener and botanist, from an earlier tree brought from America by his brother, also a botanist, in 1601. It is tied in age with another from the same source planted at the same time on the square of Saint-Julien-le-Pauvre. The Gallery was built in 1930–35 with a grant from the Rockefeller Foundation. Directly in front is a statue entitled "Science and Mystery" by Jean-Louis Schroeder, made in 1889. It depicts an old man pondering an egg, contemplating the enigma of which came first. The primary content of the gallery is the Herbier National, a collection representing 7.5 million plants collected since the founding of the museum. They are divided for study into Spermatophytes, plants which reproduce with seeds, and cryptogams, plants which reproduce with spores, such as algae, lichens and mushrooms. Many of the plants were collected by Jean Baptiste Christophore Fusée Aublet, the royal pharmacist and botanist in French Guiana. In 1775 he published his "Histoire des plantes de la Guiane Française" describing 576 genera and 1,241 species of neotropical plants, including more than 400 species that were new to science, at a time when only 20,000 plants had been described, The ground floor interior of the gallery has vestibules built in a combination of Art Deco and Neo-Egyptian styles.
The Bergmann degradation is a series of chemical reactions designed to remove a single amino acid from the carboxylic acid (C-terminal) end of a peptide. First demonstrated by Max Bergmann in 1934, it is a rarely used method for sequencing peptides. The later developed Edman degradation is an improvement upon the Bergmann degradation, instead cleaving the N-terminal amino acid of peptides to produce a hydantoin containing the desired amino acid. The Bergmann degradation follows the earlier work of Bergmann and his close colleague Leonidas Zervas, combining the organic azide degradation of the Curtius rearrangement with the Bergmann-Zervas carbobenzoxy method, which they designed to occur under relatively mild conditions so as to allow peptide sequencing. A single round of the Bergmann degradation yields an aldehyde containing the sought after amino acid residue and the remaining fragment of the original peptide in amide form.
SNX8 belongs to the sorting nexin family of proteins, which mainly contain two functional membrane-binding that allow SNXs to have different roles in endosomal sorting and protein trafficking thanks to its membrane curvature ability. To begin with, SNX-PX is a distinct phosphoinositide (PI)-binding domain. The preferential interaction of this domain with membrane lipids makes the main function of SNX-PX the targeting of proteins to phosphatidylinositol-3-phosphate (PI(3)P) to endosomes. On the other hand, the BAR (Bin/amphiphysin/Rvs) domain is a key regulator of phosphoinositide-mediated, tubular-based endosomal sorting. Accordingly, this domain also dimerizes to sense, stabilize and induce membrane curvature. The SNX-BAR proteins that contain both domains are a part of phosphoinositide-enriched, high-curvature tubular micro-domains of the endo-lysosomal network. The mammalian genome contains 12 genes coding for SNX-BAR proteins (SNX1, SNX2, SNX4, SNX9, SNX18, SNX32 and SNX33). Other domains, such as PDZ (postsynaptic density protein-95, discs-large, zona occludens-1), SH3 (Src homology 3) and RA (Ras-associated), are involved in protein-protein interactions.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.